John J. ENGELHARDT

Person

Fremont, CA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Anti-ICOS agonist antibodies and uses thereof
- Patent number 11,529,399
- Issue date Dec 20, 2022
- Bristol-Myers Squibb Company
- John J. Engelhardt
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-ICOS agonist antibodies and uses thereof
- Patent number 11,207,391
- Issue date Dec 28, 2021
- Bristol-Myers Squibb Company
- John J. Engelhardt
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-ICOS agonist antibodies and uses thereof
- Patent number 10,898,556
- Issue date Jan 26, 2021
- Bristol-Myers Squibb Company
- John J. Engelhardt
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-ICOS agonist antibodies and uses thereof
- Patent number 10,493,140
- Issue date Dec 3, 2019
- Bristol-Myers Squibb Company
- John J. Engelhardt
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-ICOS agonist antibodies and uses thereof
- Patent number 10,251,945
- Issue date Apr 9, 2019
- Bristol-Myers Squibb Company
- John J. Engelhardt
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Ipilimumab variant with enhanced ADCC
- Patent number 10,196,445
- Issue date Feb 5, 2019
- Bristol-Myers Squibb Company
- John J. Engelhardt
- C07 - ORGANIC CHEMISTRY

Patents Applicationslast 30 patents

Information Patent Application
ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF
- Publication number 20240041995
- Publication date Feb 8, 2024
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
DOSING AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CTLA-4 ANTIBODY A...
- Publication number 20240002513
- Publication date Jan 4, 2024
- Bristol-Myers Squibb Company
- Leonard P. JAMES
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
- Publication number 20230287064
- Publication date Sep 14, 2023
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
- Publication number 20200207816
- Publication date Jul 2, 2020
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF
- Publication number 20200030425
- Publication date Jan 30, 2020
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF
- Publication number 20190298816
- Publication date Oct 3, 2019
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF
- Publication number 20190175705
- Publication date Jun 13, 2019
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF
- Publication number 20190076515
- Publication date Mar 14, 2019
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
- Publication number 20180312553
- Publication date Nov 1, 2018
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF
- Publication number 20180289790
- Publication date Oct 11, 2018
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
- Publication number 20150322119
- Publication date Nov 12, 2015
- Bristol-Myers Squibb Company
- John J. ENGELHARDT
- C07 - ORGANIC CHEMISTRY

John J. ENGELHARDT

Person

Patents Grantslast 30 patents

Anti-ICOS agonist antibodies and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Ipilimumab variant with enhanced ADCC

Patents Applicationslast 30 patents

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

DOSING AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CTLA-4 ANTIBODY A...

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS